TTF1 and lung cancer: SMARCA2 and SMARCA4 deficiency was noted in 10% of nonsmall cell lung cancer cases, 80% of SMARCA2/SMARCA4 deficient tumors was also TTF-1 negative, and recently SMARCA4 loss was found to be a predictor of response to platinum based chemotherapy [8].